comprehensive -WSS

comprehensive

author：hotspot 2025-10-02 18:46:55 - browse：43972

Doctor holding a clipboard. -- health coverage from STAT — Adobe

The momentum around weight loss drugs is about to get even bigger in the wake of Novo Nordisk’s announcement that its semaglutide drug Wegovy cut the risk of cardiovascular disease by 20% in its large SELECT trial.

The full results of the study, funded by Novo, will be presented at the American Heart Association meeting in November. Doctors and researchers say they expect the findings to have a big impact on how clinicians approach the treatment of both obesity and cardiovascular disease, as well as increase the likelihood that prescriptions for obesity drugs will be covered by insurance.

But experts who spoke with STAT also cautioned that the long-term safety and efficacy of Wegovy and other weight loss drugs remain unknown. The SELECT study has yet to be peer-reviewed, and not enough information is yet available to make independent assessments of the results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Security flaws in third

explore

WSS

UpToDate has a racism problem: Dr. Stanley Goldfarb

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How many hemophilia patients actually want gene therapy?

UCLA team creates talking throat patch for voice disorders

Dexcom's push to bring CGM to type 2 diabetes patients

Security flaws in third

focus

comprehensive

focus

As demand for Covid shots wanes, Moderna seeks its next success

Security flaws in third

Wildfire smoke exposes gaps in outdoor worker protections

RaDonda Vaught links Vanderbilt hospital issues to patient death

New air purifier tech could be key to improving indoor air quality

Crowdfunding for unproven stem cell procedures spreads misinformation

Psychedelics group wrestles with new pharma identity

Crowdfunding for unproven stem cell procedures spreads misinformation

Medical records are filled with copy

President Biden's budget: Here's what you might have missed

entertainment

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Amid AI frenzy, a top HHS official's quest to create safeguards

The biotech scorecard for Q3: 15 stock

As AI in medicine takes off, can 'human in the loop' prevent harm?

AstraZeneca lung cancer study comes in below expectations

Boston's new lab space is opening empty

focus

entertainment

explore

focus